- « Previous
- Clinical Pharmacology
- Next »
Cipro I.V.
CLINICAL PHARMACOLOGY
Cipro I.V.
Absorption
Following 60-minute intravenous infusions of 200 mg and 400 mg ciprofloxacin to normal volunteers, the mean maximum serum concentrations achieved were 2.1 and 4.6 µg/mL, respectively; the concentrations at 12 hours were 0.1 and 0.2 µg/mL, respectively.
Steady-state Ciprofloxacin Serum Concentrations (µg/mL) After
60-minute I.V. Infusions q 12 h.
| Time after starting the infusion | ||||||
| Do se | 30 min. | 1 hr | 3 hr | 6 hr | 8 hr | 12 hr |
| 200 mg | 1.7 | 2.1 | 0.6 | 0.3 | 0.2 | 0.1 |
| 400 mg | 3.7 | 4.6 | 1.3 | 0.7 | 0.5 | 0.2 |
The pharmacokinetics of ciprofloxacin are linear over the dose range of 200 to 400 mg administered intravenously. Comparison of the pharmacokinetic parameters following the 1st and 5th I.V. dose on a q 12 h regimen indicates no evidence of drug accumulation. The absolute bioavailability of oral ciprofloxacin is within a range of 70-80% with no substantial loss by first pass metabolism. An intravenous infusion of 400-mg ciprofloxacin given over 60 minutes every 12 hours has been shown to produce an area under the serum concentration time curve (AUC) equivalent to that produced by a 500-mg oral dose given every 12 hours. An intravenous infusion of 400 mg ciprofloxacin given over 60 minutes every 8 hours has been shown to produce an AUC at steady-state equivalent to that produced by a 750-mg oral dose given every 12 hours. A 400-mg I.V. dose results in a Cmax similar to that observed with a 750-mg oral dose. An infusion of 200 mg ciprofloxacin given every 12 hours produces an AUC equivalent to that produced by a 250-mg oral dose given every 12 hours.
Steady-state Pharmacokinetic Parameter Following Multiple
Oral and I.V. Doses
| Parameters | 500 mg q12h, P.O. |
400 mg q12h, I.V. |
750 mg q12h, P.O. |
400 mg q8h, I.V. |
| AUC (µg•hr/mL) | 13.7 a | 12.7 a | 31.6 b | 32.9 c |
| Cmax (µg/mL) | 2.97 | 4.56 | 3.59 | 4.07 |
| a AUC0-12h bAUC 24h=AUC0-12h × 2 cAUC 24h=AUC0-8h × 3 |
||||
Distribution
After intravenous administration, ciprofloxacin is present in saliva, nasal and bronchial secretions, sputum, skin blister fluid, lymph, peritoneal fluid, bile, and prostatic secretions. It has also been detected in the lung, skin, fat, muscle, cartilage, and bone. Although the drug diffuses into cerebrospinal fluid (CSF), CSF concentrations are generally less than 10% of peak serum concentrations. Levels of the drug in the aqueous and vitreous chambers of the eye are lower than in serum.
Metabolism
Generic Name: Ciprofloxacin IV
- « Previous
- Clinical Pharmacology
- Next »
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Health Extras
Why Men Don't Go to the Doc
Experts say "American men live sicker and die younger than American women." Here are some explanations as to why.See more WebMD Videos »

